Practical Notes on the Current ESMO Consensus Guidelines for the Management of Patients with Metastatic Colorectal Cancer in Resource-Constrained Environments of Low- to Middle-Income Countries

Maurel, Jean-Marc; Tamayo, Maria Belen; Pitargue, Rosario; Ong-Cornel, Annielyn Beryl; Mehta, Piyush M.; Diouf, Doudou; Deshmukh, Chetan; Basade, Maheboob; Balde, S; Adanza-Cutillar, Eunice; Dawood, Shaheenah

doi:10.1159/000530275

Cited by 2 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This scenario is closely linked to the dietary patterns prevalent in these nations. Additionally, constrained economic development significantly impedes effective early diagnosis of colon cancer [25, 26]. Despite the current inclusion of various treatment modalities for colon cancer, such as surgery, radiotherapy, targeted therapy, and chemotherapy, neoadjuvant therapy has also become a standard treatment approach.…”

Section: Discussionmentioning

confidence: 99%

Identification of cuproptosis and ferroptosis-related subtypes and development of a prognostic signature in colon cancer

He,

Liu,

Jiang

2024

Preprint

View full text Add to dashboard Cite

Colon cancer, as a highly prevalent malignant tumor globally, poses a significant threat to human health. In recent years, ferroptosis and cuproptosis, as two novel forms of cell death, have attracted widespread attention for their potential roles in the development and treatment of colon cancer. However, the investigation into the subtypes and their impact on the survival of colon cancer patients remains understudied. In this study, utilizing data from TCGA and GEO databases, we examined the expression differences of ferroptosis and cuproptosis-related genes in colon cancer and identified two subtypes. Through functional analysis and bioinformatics methods, we elucidated pathway differences and biological characteristics between these two subtypes. By leveraging differential genes between the two subtypes, we constructed a prognostic model using univariate Cox regression and multivariate Cox regression analysis as well as LASSO regression analysis. Further survival analysis and receiver operating characteristic curve analysis demonstrated the model’s high accuracy. To enhance its clinical utility, we evaluated the clinical significance of the model and constructed a nomogram, significantly improving the predictive ability of the model and providing a new tool for prognostic assessment of colon cancer patients. Subsequently, through immune-related analysis, we revealed differences in immune cell infiltration and immune function between high- and low-risk groups. Further analysis of the relationship between the model and immune cells and functions revealed potential therapeutic targets. Drug sensitivity analysis revealed associations between the expression of model-related genes and drug sensitivity, suggesting their involvement in tumor resistance through certain mechanisms. AZD8055_1059, Bortezomib_1191, Dihydrorotenone_1827, and MG-132_1862 were more sensitive in the high-risk group. Finally, we analyzed differential expression of model-related genes between tumor tissues and normal tissues, validated through real-time quantitative PCR. In summary, our study provides a relatively accurate prognostic tool for colon cancer patients, offering guidance for treatment selection and indicating the potential of immunotherapy in colon cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of cuproptosis and ferroptosis-related subtypes and development of a prognostic signature in colon cancer

He,

Liu,

Jiang

2024

Preprint

View full text Add to dashboard Cite

show abstract

Complete remission in a pretreated, microsatellite-stable, KRAS-mutated colon cancer patient after treatment with sintilimab and bevacizumab and platinum-based chemotherapy: a case report and literature review

He,

Li,

Wang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Metastatic colon cancer remains an incurable disease, and it is difficult for existing treatments to achieve the desired clinical outcome, especially for colon cancer patients who have received first-line treatment. Although immune checkpoint inhibitors (ICIs) have demonstrated durable clinical efficacy in a variety of solid tumors, their response requires an inflammatory tumor microenvironment. However, microsatellite-stable (MSS) colon cancer, which accounts for the majority of colorectal cancers, is a cold tumor that does not respond well to ICIs. Combination regimens open the door to the utility of ICIs in cold tumors. Although combination therapies have shown their advantage even for MSS colon cancer, it remains unclear whether combination therapies show their advantage in patients with pretreated metastatic colon cancer. We report a patient who has achieved complete remission and good tolerance with sintilimab plus bevacizumab and platinum-based chemotherapy after postoperative recurrence. The patient had KRAS mutation and MSS-type colon cancer, and his PD-1+CD8+ and CD3−CD19−CD14+CD16−HLA-DR were both positive. He has achieved a progression-free survival of 43 months and is still being followed up at our center. The above results suggest that this therapeutic regimen is a promising treatment modality for the management of pretreated, MSS-type and KRAS-mutated metastatic colorectal cancer although its application to the general public still needs to be validated in clinical trials.

show abstract

Practical Notes on the Current ESMO Consensus Guidelines for the Management of Patients with Metastatic Colorectal Cancer in Resource-Constrained Environments of Low- to Middle-Income Countries

Abstract: Letter (no abstract)

Cited by 2 publications

References 16 publications

Identification of cuproptosis and ferroptosis-related subtypes and development of a prognostic signature in colon cancer

Identification of cuproptosis and ferroptosis-related subtypes and development of a prognostic signature in colon cancer

Complete remission in a pretreated, microsatellite-stable, KRAS-mutated colon cancer patient after treatment with sintilimab and bevacizumab and platinum-based chemotherapy: a case report and literature review

Contact Info

Product

Resources

About